Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 jun 2014 - 07:37
Statutaire naam
Galapagos NV
Titel
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
Bericht
Review of CF and other highlighted programs in today's R&D update
GLPG0634 DARWIN 1 study to deliver 12 week topline data in Q1 2015
GLPG0974 shows biomarker effect & good safety in ulcerative colitis patients, but lacks clinical improvement in 4 week Proof-of-Concept study
GLPG1492 mode of action scalable to ESKAPE and other pathogens
Multiple Phase 2 readouts with novel modes-of-action in coming two years
Live webcast presentation today at 8:00 am ET/2:00 pm CET on www.glpg.com,
call number +32 2 404 0660, confirmation code 2952966
Mechelen, Belgium; 17 June 2014 - Galapagos NV (Euronext: GLPG) will give an R&D Update today in New York City, highlighting the company strategy, progress and plans for its portfolio of more than 35 R&D programs.
Datum laatste update: 27 juli 2024